Vanderbilt Integrated Center of Excellence in Maternal and Pediatric Precision Therapeutics (VICE-MPRINT)

范德比尔特母婴精准治疗卓越综合中心 (VICE-MPRINT)

• 批准号: 10480926
• 负责人: PRINCE Joseph KANNANKERIL
• 金额: $ 125万
• 依托单位: VANDERBILT UNIVERSITY MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-10 至 2026-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10480926
• 关键词: Academic Medical Centers; Address; Adoption; Affect; Algorithms; Area; Artificial Intelligence; Attitude; Bioinformatics; Caring; Child; Childhood; Clinical; Clinical Research; Collaborations; Collection; Communities; Data; Data Linkages; Data Science; Data Set; Development; Devices; Disabled Persons; Discipline of obstetrics; Disease; Dose; Electronic Health Record; Ensure; Environment; Fostering; Foundations; Future; Generations; Genes; Genomics; Goals; Grant; Health; Healthcare; Individual; Infant; Infrastructure; International; Knowledge; Label; Lactation; Leadership; Logistics; Machine Learning; Methodology; Modeling; Mothers; National Institute of Child Health and Human Development; Nature; Neonatal Abstinence Syndrome; Opioid; Outcome; Pediatrics; Persons; Pharmaceutical Preparations; Pharmacogenetics; Pharmacogenomics; Pharmacology Study; Phenotype; Physicians; Population; Positioning Attribute; Postpartum Period; Postpartum Women; Precision therapeutics; Pregnancy; Pregnant Women; Research; Research Personnel; Research Project Grants; Research Training; Resources; Sampling; Scientist; Strategic Planning; Supervision; Testing; Therapeutic; Therapeutic Human Experimentation; Time; Training; Training Activity; Training Support; Translational Research; Translations; United States National Institutes of Health; Variant; Woman; Work; base; biomedical informatics; clinical care; clinically actionable; cohort; data sharing; disability; disparity reduction; education resources; experience; healthy pregnancy; human disease; implementation science; improved; innovation; interdisciplinary approach; investigator training; knowledge base; large datasets; multidisciplinary; novel; opioid exposure; opioid use disorder; precision medicine; pregnant; programs; response; support tools; therapeutically effective; tool; training opportunity; translational applications

PROJECT SUMMARY / ABSTRACT - OVERALL There is a rapidly expanding knowledge base enabling precision therapeutics for a number of human diseases, but there are significant unmet needs in evidence generation to support translation to the treatment of children and pregnant/post-partum women. The recent widespread adoption of electronic health records (EHRs) and the linkage of these data to other large datasets represents an unprecedented opportunity for clinical research and discovery. The goals of this Center of Excellence in Maternal and Pediatric Precision Therapeutics are: to address key knowledge gaps and perform clinical research in pharmacogenomics and neonatal opioid withdrawal syndrome; to leverage data science methodologies and develop novel tools that support maternal and pediatric precision therapeutics research; and to enhance training for maternal and pediatric precision therapeutics at the local, regional, and national levels. We bring to this effort a unique collection of investigators, institutional support, tools, and resources that enable a paradigm-shift from current norms of slow, incremental progress. Project 1 will: use a community engaged approach to illuminate knowledge of, attitudes about, and priorities for pharmacogenomics; validate pharmacogenomic associations for maternal and pediatric populations using the innovative and generalizable strategy of EHR phenotyping; and identify and quantify variants with unknown functional consequence in diverse individuals to inform future research efforts and reduce disparities. Project 2 will: develop and validate EHR-based algorithms to identify a cohort of opioid- exposed infants and their mothers (dyads) and create a novel linkage of these data to state-wide data; test the hypothesis that use of medications for opioid use disorder is associated with improved early outcomes; and test the hypothesis that opioid use disorder treatment is associated with improvements in the novel longitudinal outcome of dyadic stability. These projects are led by multidisciplinary teams that include Investigators in Pediatrics and Obstetrics, and who are nationally recognized leaders in their respective fields. Both Projects will be supported by a Scientific Core – the Phenotyping Support Core - which enhances each project with expert phenotyping, machine learning/artificial intelligence, and experience in generalizing and disseminating phenotyping approaches. An Administrative Core will provide logistical support for the Center, supervise training opportunities, and ensure scientific interchange within the CET and with the MPRINT Hub. This work will contribute to innovative approaches to precision therapeutics for mothers and children and will develop the educational infrastructure to support the training of physician-scientists to support further advances well into the future.

项目概要/摘要 - 总体 知识库正在迅速扩大，能够对许多人类疾病进行精准治疗， 但在支持转化为儿童治疗的证据生成方面存在大量未满足的需求 以及孕妇/产后妇女。最近广泛采用电子健康记录（EHR）和 这些数据与其他大型数据集的链接为临床研究提供了前所未有的机会 和发现。该母婴精准治疗卓越中心的目标是： 解决关键知识差距并进行药物基因组学和新生儿阿片类药物的临床研究 戒断综合症；利用数据科学方法并开发支持母亲的新工具 和儿科精准治疗研究；加强母婴精准培训 地方、区域和国家各级的治疗。我们为此努力带来了一系列独特的 研究者、机构支持、工具和资源，以实现当前规范的范式转变 缓慢、渐进的进展。项目 1 将： 使用社区参与的方法来阐明以下知识： 对药物基因组学的态度和优先事项；验证母亲的药物基因组学关联 和儿科人群使用 EHR 表型分析的创新和通用策略；并识别和 量化不同个体中具有未知功能后果的变异，为未来的研究工作提供信息 并缩小差距。项目 2 将：开发和验证基于 EHR 的算法来识别阿片类药物队列 暴露婴儿及其母亲（二元组），并将这些数据与全州数据建立新颖的联系；测试 假设使用治疗阿片类药物使用障碍的药物与改善早期结果有关；和 检验阿片类药物使用障碍治疗与小说改善相关的假设 二元稳定性的纵向结果。这些项目由多学科团队领导，其中包括 儿科和产科研究人员，是各自领域全国公认的领导者。 这两个项目都将得到科学核心（表型支持核心）的支持，该核心增强了每个项目 具有专家表型分析、机器学习/人工智能以及概括和总结经验的项目 传播表型分析方法。行政核心将为该中心提供后勤支持， 监督培训机会，并确保 CET 内以及与 MPRINT 中心的科学交流。 这项工作将有助于为母亲和儿童提供精准治疗的创新方法，并将 发展教育基础设施，支持医师科学家的培训，以支持进一步的进步 展望未来。